|
|
Article: Study: Pimecrolimus significantly modifies course of skin disease in infants.(atopic eczema)(Brief Article)
- Article from:
- Immunotherapy Weekly
- Article date:
- October 2, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Treatment of the early symptoms of the itching skin disease, atopic eczema, with the new nonsteroid cream Elidel (pimecrolimus) significantly modifies the disease course in infants by reducing the incidence of flares and improving its overall control, according to a study published in the August issue of the Journal of Allergy and Clinical Immunology.
Additionally, the study showed that Elidel is more effective than conventional therapy in the long-term control of pruritus (itching) and the signs of atopic eczema (also known as atopic dermatitis).
"In the past we have had very few options for treating eczema in ...
Related newspaper, magazine, and journal articles:
|